In a patient with gastritis, a procalcitonin level of 0.16 ng/mL and a C‑reactive protein level of 62 mg/L, should antibiotics be administered?

No, antibiotics are NOT indicated for this patient with gastritis based on these inflammatory markers alone.

In a patient presenting with gastritis, a procalcitonin (PCT) of 0.16 ng/mL and CRP of 62 mg/L do not justify antibiotic treatment unless there is confirmed bacterial infection requiring eradication therapy.

Interpretation of Biomarkers in Gastritis

Your patient's PCT level of 0.16 ng/mL falls well below the threshold typically associated with bacterial infection requiring antibiotics. Research demonstrates that:

• PCT levels <0.5 ng/mL generally indicate low probability of bacterial infection requiring antimicrobial therapy 1, 2
• In gastroenteritis specifically, PCT showed only 60.3% sensitivity and 62.6% specificity for bacterial causes, with improved performance only in febrile adults (≥38°C) 3
• For H. pylori-associated gastritis specifically, PCT levels averaged 1.39 ng/mL in infected patients versus 0.35 ng/mL in uninfected patients, but PCT remained an ineffective marker for diagnosis or treatment monitoring 4

The elevated CRP of 62 mg/L is non-specific and commonly seen in gastritis regardless of etiology:

• CRP elevates with mucosal inflammation severity but does not distinguish between infectious and non-infectious causes 5, 6
• Mean CRP in chronic gastritis patients ranges from 2.2-2.85 mg/dl, with higher levels correlating with inflammation severity rather than need for antibiotics 5, 6
• CRP showed 79% sensitivity but 78.6% specificity for bacterial gastroenteritis, meaning significant false-positive rates 3

When Antibiotics ARE Indicated in Gastritis

Antibiotics should only be prescribed for gastritis in these specific scenarios:

1. Confirmed H. pylori infection requiring eradication therapy:

   • First-line: Bismuth quadruple therapy (bismuth + PPI + tetracycline + metronidazole) for 10-14 days 7
   • Alternative when bismuth unavailable: Concomitant 4-drug therapy (PPI + clarithromycin + amoxicillin + metronidazole) 7
   • Diagnosis requires endoscopic biopsy with histology/culture, rapid urease test, or stool antigen testing—NOT inflammatory markers 7

2. Documented bacterial superinfection with systemic signs of sepsis (PCT typically >0.5-2.0 ng/mL in true bacterial infections)

Critical Pitfalls to Avoid

• Do not use PCT or CRP alone to justify antibiotic initiation in gastritis—these markers reflect inflammation, not necessarily bacterial infection requiring treatment 4
• Provider-level factors (not patient factors) were the primary driver of inappropriate antibiotic continuation despite low PCT levels in 55% of hospitalized patients 1
• Empiric antibiotics for gastritis without confirmed H. pylori contributes to antibiotic resistance, which is already compromising H. pylori eradication rates globally 7

Recommended Approach for Your Patient

Given PCT 0.16 ng/mL (low) and CRP 62 mg/L (elevated but non-specific):

1. Withhold antibiotics at this time
2. Test for H. pylori if not already done (stool antigen, urea breath test, or endoscopic biopsy)
3. Initiate PPI therapy for symptomatic gastritis management
4. Reassess clinically for signs of bacterial infection (fever, hemodynamic instability, rising PCT >0.5 ng/mL)
5. Only start antibiotics if H. pylori confirmed OR patient develops clear evidence of bacterial infection

The biomarker profile you describe reflects mucosal inflammation consistent with gastritis but does not meet criteria for antibiotic therapy.